Abstract:BACKGROUND: Cancer that originates in the bone, termed primary bone cancer, is rare. Osteosarcoma (OS) occurs primarily in growing bone tissue and is more prevalent in children and adolescents. OS in adults is rare, with 3 to 5 cases per million population per year worldwide. There are limited data on treatment-related prognosis and adverse reactions in adults reported in the literature.OBJECTIVES: The alms of this study were to investigate factors that influence serum methotrexate (MTX) concentrations used in chemotherapy in Chinese adult patients with OS, and to determine the correlations (based on age, sex, and dosage), if any, between MTX and prognosis, in terms of disease-free survival (DFS) and overall survival (OAS), and tolerability.METHODS: Adult patients aged >= 30 years with OS received >= 3 courses (2 courses before surgery and 3-4 Courses postsurgery) of high-dose MTX (6 or 8 g/m(2)) combined chemotherapy. The regimen consisted of day 1: MTX + folinic acid (herein referred to as citrovorum factor rescue); day 8: cisplatin; days 21 to 25: ifosfamide + mesna; and day 21: doxorubicin. Serum MTX concentrations were assessed immediately after the end of infusion (baseline) and at 24 and 48 hours using high-performance liquid chromatography. Changes in serum MTX concentrations, factors that influence serum MTX concentrations, and the relationship between serum MTX concentrations and prognosis and tolerability (determined by adverse reactions) were analyzed. Patients received a second course of treatment after a 3-week period.RESULTS: Ninety patients (58 men, 32 women; age range, 30-67 years) with OS were included in the study. A total of 532 courses of combined chemotherapy were administered. The serum MTX concentrations ranged widely at baseline (244.31-929.68 mol/L, C-min and C-max, respectively) and at 24 hours (0.73-28.24 mol/L, respectively), suggesting that the serum MTX concentrations varied significantly between different individuals and within the same individual at different time points. The serum MTX concentrations in similar to 23% of cases (122/532) determined at 24 and/or 48 hours were numerically higher than the safety values (according to Nirenberg's reference: irreversible damage if MTX concentration was > 10 mu mol/L and > 1 mu mol/L at 24 and 48 hours, respectively). No correlation was found between high serum MTX concentration at baseline and high serum MTX concentration at 24 hours (r = 0.401). The prevalences of the 3 most common adverse reactions In these patients were depressed white blood cell count (44.03%), dental ulcer (23.0%), and rash (18.0%). However, in the remaining 410 courses in which serum MTX concentrations were lower than the safety values, these prevalences were 14.6%, 3.9%, and 2.4%, respectively. Neither age nor sex was significantly associated with MTX C-max, but dosage was (P < 0.05). Patients with a serum MTX C-max concentration >500 mu mol/L at baseline had a significantly longer DFS rate than those with <= 500 mu mol/L (P = 0.040). There were no significant between-group differences in the OAS rates.CONCLUSIONS: In these Chinese patients with OS, serum MTX concentrations measured at different time points were varied. The findings suggest that adverse reactions occurred in patients whose serum MTX concentrations at 24 and/or 48 hours were higher than the safety values. The dosage appeared to have influenced MTX C-max, while sex and age did not, and the C-max was significantly related to DFS but not OAS. (Curr Ther Res Clin Exp. 2009;70:150-160) (C) 2009 Excerpta Medica Inc.

Risk factors associated with liver damage induced by high-dose methotrexate treatment of osteosarcoma

Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management.

Relationship of Serum Methotrexate Concentration in High-Dose Methotrexate Chemotherapy to Prognosis and Tolerability: A Prospective Cohort Study in Chinese Adults with Osteosarcoma

Monitoring the plasma concentration of high-dosage of methotrexate during chemotheraphy for osteosarcoma and its clinical significance

High dose methotrexate in chemotherapy for osteosarcoma of the extremities: 63 cases report

Measurements of Serum Drug Level for MTX and Analysis of Its Factors That Work on During the Chemotherapy of Osteosarcoma

Serum concentration monitoring and significance of methotrexate in patients with osteosarcoma undergoing chemotherapy

High-Dose Methotrexate (HD-MTX) Used As an Adjunct with Other Chemotherapeutics for the Treatment of Osteosarcoma

The Effect of the Plasma Methotrexate Concentration During High-Dose Methotrexate Therapy in Childhood Acute Lymphoblastic Leukemia.

Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma

Management of side effect related to HD-MTX combination therapy for osteosarcoma

MTHFR Variant is Associated with High-Dose Methotrexate-Induced Toxicity in the Chinese Osteosarcoma Patients

More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate.

Nomogram predicting leukopenia in osteosarcoma after high-dose methotrexate chemotherapy

Risk factors for high‐dose methotrexate associated toxicities in patients with primary central nervous system lymphoma

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

Correlation between gene polymorphism and adverse reactions of high-dose methotrexate in osteosarcoma patients: a systematic review and meta-analysis

Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate

Analysis of Prognostic Factors in 333 Chinese Patients with High-Grade Osteosarcoma Treated by Multidisciplinary Combined Therapy.

Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.

Clinical study of high dose MTX combined with cisplatin in the treatment of osteosarcoma